Measurement of baseline serum SDF-1 levels as a predictive biomarker for outcomes in the NCIC CTG MA.14 trial of octreotide, a somatostatin analogue in postmenopausal breast cancer.
A. Aguilar-Mahecha
No relevant relationships to disclose
M. Basik
No relevant relationships to disclose
J. W. Chapman
No relevant relationships to disclose
K. Jahan
No relevant relationships to disclose
S. Hassan
No relevant relationships to disclose
L. Zhu
No relevant relationships to disclose
C. F. Wilson
No relevant relationships to disclose
K. I. Pritchard
Consultant or Advisory Role - Abraxis BioScience (U); AstraZeneca (U); Boehringer Ingelheim (U); Pfizer (U); Roche (U)
Honoraria - Abraxis BioScience; AstraZeneca; Boehringer Ingelheim; Pfizer; Roche
Expert Testimony - AstraZeneca (U); Novartis (U)
L. E. Shepherd
No relevant relationships to disclose
M. N. Pollak
No relevant relationships to disclose